BEHAVIOR OF IVERMECTIN ON MORTALITY FROM COVID-19: SYSTEMATIC REVIEW
Received: 17.09.2021; Revised: 26.10.2021, Accepted: 22.11.2021, Published Online: 16.12.2021
Leveau-Bartra Harry R.
Private University San Juan Bautista. Filial-Ica, General Surgeon-Biostatistics, (ORCID: https://orcid.org/0000-0001-9632-7793)
Chávez-Navarro Juan R.
National University Federico Villarreal, Bachelor of Psychology, (ORCID: https://orcid.org/0000-0002-0187-6165)
Calle Vilca Luis A.
Private University San Juan Bautista. Filial-Ica, Doctor of Public Health, (ORCID: https://orcid.org/0000-0003-0473-3175)
Guerrero Ortiz Hilda A.
Private University San Juan Bautista. Filial-Ica, Obstetrician-Gynecologist, (ORCID: https://orcid.org/0000-0003-3292-6644)
Mejia Lengua Carmen E.
National University San Luis Gonzaga, Doctor in Nursing, (ORCID: 0000-0002-3660-2586)
Leveau-Vásquez Harry I
Private University San Juan Bautista. Filial-Ica, Surgeon, (ORCID: https://orcid.org/0000-0001-8093-0475)
Leveau Vásquez Isabella K
Private University San Juan Bautista. Filial-Ica, Surgeon, (ORCID: https://orcid.org/0000-0003-2690-8861)
Luján Divizzia Beatriz M
National University of Ucayali, Surgeon, (ORCID: https://orcid.org/0000-0002-8694-3370)
The purpose of the systematic review was to analyze the studies carried out on the effects of ivermectin on the mortality of patients diagnosed with COVID-19. Methodology. Cross-sectional, retrospective, analytical and observational research, the studies were obtained from the review of articles published in the main databases. A systematic review was previously carried out to finally show the results of the meta-analysis. Only 4 studies submitted to statistical analysis met the inclusion criteria required in this meta-analysis, which is the possibility of reproduction, the most specific possible, not being necessary to have a study in pairs. Results: The heterogeneity of the studies is low 18.2%, the Odds ratio in the fixed effects model is 0.42 (95% CI = 0.2640 – 0.6754) in a global sample of 660 patients belonging to 4 studies. Publication bias is not significant. Conclusions: The global OR found in the fixed effects model indicates that ivermectin administered to patients diagnosed with COVID-19 reduces the probability of death by up to 57.8%. No research analyzed in the meta-analysis is peer-reviewed.
Keywords: Ivermectin, COVID-19 mortality